The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment
- 1 March 2012
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 11 (5), 326-329
- https://doi.org/10.1016/j.autrev.2011.06.011
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practiceAutoimmunity Reviews, 2011
- Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registryArthritis & Rheumatism, 2010
- The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2010
- Biologics for rheumatoid arthritis: an overview of Cochrane reviewsSao Paulo Medical Journal, 2010
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studiesAnnals Of The Rheumatic Diseases, 2009
- Adverse events and efficacy of TNF- blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patientsRheumatology, 2009
- Advances in the pathogenesis and treatment of IBDClinical Immunology, 2009
- Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosusExpert Opinion on Drug Safety, 2008
- Premature atherosclerotic cardiovascular disease in systemic lupus erythematosusArthritis & Rheumatism, 2007